In support of the development of novel therapies for drug discovery in neurodegenerative diseases, Discovery from Charles River now offers autoradiography (ARG) assays. Methodologies to study the competitive binding of ligands, receptor densities, metabolic changes and functionality of receptors with their corresponding agonist have been established. Traditionally, autoradiography has been done by exposing samples on films or phosphoscreens – a process which takes days or months, depending on the radioisotope being employed. Now we are able to use real-time imaging of radioisotopes, and quantitative data can be obtained within hours of samples being scanned. The combination of these assays provides a powerful tool to comprehensively measure responses in disease models to novel molecules quickly and cost-efficiently.
Why Is This Important?
Progressive loss of neurons is a typical characteristic in many neurological disorders. Therefore, alterations in receptor density and glucose utilization in the brain are studied and employed in clinical diagnosis. As density and ligand affinity to receptors are important factors, the activation of certain receptors is crucial to the understanding of the potency of novel compounds, as well the response to treatment. G-protein-coupled receptors (GPCR) are involved in a wide variety of physiological processes because they activate intercellular signal transduction pathways and ultimately cellular responses. Neurologically interesting targets include serotonin, dopamine, GABA, and glutamate receptors.
Download our poster to learn more about how autoradiography offers a powerful tool to move your study forward.